Stocks · News reference
Market-Moving News for September 18th
TCRT: 69% | Alaunos Therapeutics On Thursday Filed Patent Application "Identification Of Neoantigen-Reactive T Cell Receptors" MEDS: 24% | DataMeds AI Settles Litigation Related To Outstanding Debt And
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
DataMeds AI Settles Litigation Related To Outstanding Debt And Receivables Related To The 2023 Wellgistics Agreement; Company Retired ~364,099 MEDS Shares And Paid $450K In Cash
Litigation related to outstanding debt and receivables related to the May 11, 2023 Wellgistics, LLC Membership Purchase Interest Agreement (the "Settlement Agreement") that were previously carried on the
DataMEDS AI Enters Settlement Agreement On Sept 11, 2026; Expects To Extinguish $19M In Liability From Agreement
On September 11, 2026, DataMEDS AI, Inc. (the "Company") entered into a settlement agreement and release (the "Agreement") with Brian Norton, individually and as Seller Representative ("Norton"),
TCRT stock has given up its prior gain. Alaunos Therapeutics shares were trading higher after the company filed a patent application for "Identification Of Neoantigen-Reactive T Cell Receptors"
Alaunos Therapeutics Announces $1.12M Direct Offering Of 380,469 Shares And Warrants To Purchase Up To 386,654 Shares At $1.46 Per Share
The offering is expected to close on or about September 21, 2026, subject to the satisfaction of customary closing conditions.The Company intends to use the net proceeds from the offering primarily for general working
Alaunos Therapeutics shares are trading higher after the company filed a patent application for "Identification Of Neoantigen-Reactive T Cell Receptors"